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Relevant bibliography 
The role of the complement system against N. meningitidis is well established. Individuals deficient in components of the 
alternative (AP) and terminal complement pathways are highly predisposed to meningococcal infections5. 
 
Factor H (fH) is a regulatory protein of the alternative complement pathway that can inhibit the complement system 
action. This protein binds to host cells due to its glycosaminoglycans (GAGs) affinity. Because of GAGs are not found on the 
bacterial cell surface, fH can inhibit the complement system attack in host cells preferably5. 
N. meningitidis use several mechanisms to evade killing by human complement. Capturing host fH permits meningococci 
disarm the AP and downregulate its action. Expression of surface proteins that bind to fH increases bacterium resistance to 
complement system attack5. 
 
 
 
 
Figure 2. Molecular structure of the 
AP of complement components6. 
Three of the most important meningococcal proteins that bind to fH are: 
 
• fHbp: N. meningitidis strains with a fHbp gene deletion lose binding capacity to fH 
and are more susceptible to complement attack. This antigen is a clear candidate for a 
meningococcal serogroup B vaccine; it is cell surface exposed, it is present in more 
than 99% of all invasive strains, it is expressed during infection and it generates 
protective bactericidal antibodies7. 
 
 
• NspA: Recombinant NspA expressed in E. coli and purified does not have the same 
conformation as the protein present in the meningococcal outer membrane. For this 
reason, the first vaccine approximation does not elicit a bactericidal antibody 
response. Protective antibodies may be directed against conformational epitopes of 
the native protein8. 
 
 
• PorB2: It is one of the most abundant outer membrane proteins in the bacterium. 
Because of its low affinity interaction with fH, its expression downregulates the AP of 
complement9. 
 
 
Objectives Vaccine design 
Possible benefits 
Four strains are appropriately chosen to be genetically modified. 
Each strain naturally expresses the antigen which will be over-
expressed (Table 1). 
Three genes are inactivated to improve vaccine safety and to 
reduce the possibility of inducing autoimmunity: ΔsynX (blocks sialic 
acid synthesis), ΔlgtA (blocks lacto-N-neotetraose expression) and 
ΔlpxL1 (reduces LOS endotoxicity)10. 
Enhanced expression of the desired antigen is achieved by inserting 
a second copy of the corresponding gene in the nadA locus (Fig. 3). 
Vaccine strain 
name 
Derived 
from 
ΔlpxL1 ΔsynX ΔlgtA 
Over-
expression of 
S1 PMB1745 Yes Yes Yes fHbp A05 
S2 M1573 Yes Yes Yes fHbp B01 
S3 H44/76 Yes Yes Yes NspA 
S4 2996 Yes Yes Yes PorB2 
Table 1. Vaccine strains with their genetic modifications. 
Figure 3. Plasmid used for the transformation of the meningococcal strains. 
Each strain is transformed with its corresponding genic construction, in which 
the gene of interest varies. 
 Antigens included in this vaccine 
fulfil the same function: Binding 
to fH. Moreover, these molecules   
present low variability between 
meningococcal strains. 
 
 Achieving bactericidal antibodies 
against these proteins would 
produce loss of bacterial virulence 
and an increased susceptibility   
of these bacteria towards 
elimination by the complement 
system. 
 
 The technique used in this work 
could be applied to a universal 
vaccine design against the main 
meningococcal serogroups, trough 
the expression of the appropriate 
antigens. 
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The main objective of this work is to develop a novel 
meningococcal serogroup B vaccine. This vaccine consists in 
NOMVs (Native Outer Membrane Vesicles) over-expressing 
these proteins: 
• fHbp (A05 and B01 variants) 
• NspA 
• PorB2 
 
 
 
 
Figure 1. Worldwide 
distribution of the 
most prevalent 
Neisseria 
meningitidis 
serogroups4. 
Neisseria meningitidis is a Gram-negative diplococcus bacterium that causes a great number of deaths worldwide1. The most common form of meningococcal 
disease is meningitis, which often occurs as epidemics. Despite appropriate treatment, the case-fatality rate is around 10%2.  
The highest incidence rates are found in the “meningitis belt”, which extends from Senegal to Ethiopia (Fig. 1). In this area, A, C, W135 and X are the major disease 
causing meningococcal serogroups. The development of capsular polysaccharide-conjugated vaccines has allowed the prevention of disease caused by these 
serogroups1,2.  
On the other hand, there is a great meningococcal serogroup B incidence in Europe and the USA. Its capsular polysaccharide is poorly immunogenic due to its 
antigenic structure, which mimics the cell surface glycoproteins of human neurological tissue. For this reason, developing a group B vaccine has supposed a true 
challenge1. 
Reverse vaccinology has allowed identification of new vaccine candidates. The first meningococcal serogroup B vaccine based on this technique (Bexsero®) was 
approved in Europe and Australia in 20131,3. 
In this work, another approach to a vaccine development against Neisseria meningitidis serogroup B is proposed. 
Using NOMVs present several advantages than using classic 
detergent-extracted OMVs10:  
• LOS and lipoproteins are not depleted from the first 
vesicles. 
• Surface exposure of membrane proteins is similar to that 
on the intact bacterium. 
• Retaining lipoproteins allows some proteins to be present 
in the vaccine at increased levels. 
 
Expression of key epitopes and the level at which they are 
expressed are verified by colony blotting and Western blotting, 
respectively10. 
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